SpectraCure AB (publ) (SPEC.ST)
SEK 3.59
(15.81%)
SEK 3.59
(15.81%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 6.71 Million SEK | 148.78% |
| 2022 | 2.7 Million SEK | -44.93% |
| 2021 | 4.9 Million SEK | -8.59% |
| 2020 | 5.36 Million SEK | -20.1% |
| 2019 | 6.71 Million SEK | 0.0% |
| 2018 | - SEK | 0.0% |
| 2017 | - SEK | 0.0% |
| 2016 | - SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 6.5 Million SEK | -3.1% |
| 2024 Q2 | 6.11 Million SEK | -6.04% |
| 2023 Q1 | 2.08 Million SEK | -22.96% |
| 2023 FY | 6.71 Million SEK | 148.78% |
| 2023 Q4 | 6.71 Million SEK | -6.98% |
| 2023 Q3 | 7.22 Million SEK | -12.19% |
| 2023 Q2 | 8.22 Million SEK | 295.34% |
| 2022 Q1 | 4.53 Million SEK | -7.61% |
| 2022 FY | 2.7 Million SEK | -44.93% |
| 2022 Q4 | 2.7 Million SEK | -18.26% |
| 2022 Q3 | 3.3 Million SEK | -15.7% |
| 2022 Q2 | 3.91 Million SEK | -13.51% |
| 2021 FY | 4.9 Million SEK | -8.59% |
| 2021 Q1 | 5.03 Million SEK | -6.23% |
| 2021 Q2 | 5.72 Million SEK | 13.88% |
| 2021 Q3 | 5.46 Million SEK | -4.54% |
| 2021 Q4 | 4.9 Million SEK | -10.33% |
| 2020 Q1 | 6.45 Million SEK | -3.78% |
| 2020 Q2 | 6.04 Million SEK | -6.46% |
| 2020 Q3 | 5.62 Million SEK | -6.98% |
| 2020 Q4 | 5.36 Million SEK | -4.56% |
| 2020 FY | 5.36 Million SEK | -20.1% |
| 2019 Q2 | 9.42 Million SEK | 939.58% |
| 2019 Q1 | 907 Thousand SEK | 0.0% |
| 2019 FY | 6.71 Million SEK | 0.0% |
| 2019 Q4 | 6.71 Million SEK | 3.02% |
| 2019 Q3 | 6.51 Million SEK | -30.89% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 FY | - SEK | 0.0% |
| 2018 Q4 | - SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 Q1 | - SEK | 0.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2017 Q4 | - SEK | 0.0% |
| 2017 FY | - SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 FY | - SEK | 0.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 Q4 | - SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2015 Q4 | - SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 Q2 | - SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| 2014 Q4 | - SEK | 0.0% |
| 2014 Q1 | - SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Acarix AB (publ) | - SEK | -Infinity% |
| ADDvise Group AB (publ) | 1.61 Billion SEK | 99.584% |
| ADDvise Group AB (publ) | 1.61 Billion SEK | 99.584% |
| Arcoma AB | 3.87 Million SEK | -73.431% |
| Bactiguard Holding AB (publ) | 233.09 Million SEK | 97.118% |
| BICO Group AB (publ) | 1.85 Billion SEK | 99.638% |
| Boule Diagnostics AB (publ) | 166.1 Million SEK | 95.956% |
| CellaVision AB (publ) | 64.7 Million SEK | 89.619% |
| Clinical Laserthermia Systems AB (publ) | 454 Thousand SEK | -1379.515% |
| Chordate Medical Holding AB (publ) | - SEK | -Infinity% |
| C-Rad AB (publ) | 1.8 Million SEK | -273.167% |
| Duearity AB (publ) | 10.58 Million SEK | 36.524% |
| Dignitana AB (publ) | 19.1 Million SEK | 64.84% |
| Episurf Medical AB (publ) | 5.2 Million SEK | -29.173% |
| Getinge AB (publ) | 8.07 Billion SEK | 99.917% |
| Scandinavian Real Heart AB (Publ) | 8.24 Million SEK | 18.578% |
| Iconovo AB (publ) | 7.72 Million SEK | 13.048% |
| Integrum AB (publ) | 6.42 Million SEK | -4.558% |
| Luxbright AB (publ) | 206.02 Thousand SEK | -3160.3% |
| Mentice AB (publ) | 9.55 Million SEK | 29.716% |
| OssDsign AB (publ) | 3.15 Million SEK | -113.238% |
| Paxman AB (publ) | 13.57 Million SEK | 50.501% |
| Promimic AB (publ) | - SEK | -Infinity% |
| Qlife Holding AB (publ) | 20.73 Million SEK | 67.599% |
| SciBase Holding AB (publ) | 6.79 Million SEK | 1.177% |
| ScandiDos AB (publ) | - SEK | -Infinity% |
| Sectra AB (publ) | 31.78 Million SEK | 78.869% |
| Sedana Medical AB (publ) | 4.3 Million SEK | -55.992% |
| Senzime AB (publ) | 11.46 Million SEK | 41.428% |
| Stille AB | 62.94 Million SEK | 89.328% |
| Vitrolife AB (publ) | 2.08 Billion SEK | 99.678% |
| Xvivo Perfusion AB (publ) | 31.43 Million SEK | 78.633% |